Molecular detection and follow-up of the minimal residual disease in AML and CML patients

Genetic aberrations associated with the pathogenesis of the various types of acute and chronic leukemias gave the possibility for the precise diagnosis, prognosis, and monitoring of minimal residual disease. Specific chromosomal translocations associated with acute myeloid leukemia (AML) lead to the creation of fusion transcripts (protein). The most common translocations in AML, which are used as markers for monitoring the disease, are:

  • t(15; 17) PML/RAR
  • t(8; 21) AML/ETO
  • t(9 ; 22) BCR-ABL (p190, p210)
  • inv(16) CBF/MYH11

Material used for the detection of these translocations is obtained by isolating RNA from the bone marrow or peripheral blood mononuclear cells, cDNA synthesis and by PCR performed using specific programs with appropriate primers and appropriate controls. For minimal residual disease monitoring we perform two-step PCR („nested“ PCR) using two sets of primers, with a sensitivity of 1:1 000 000.

It is necessary to deliver 4 to 5 ml of bone marrow or peripheral blood (depending on the disease phase) using 3.8% sodium citrate as anticoagulant in vol/vol ratio 1:9. The sample is required to be delivered fresh, without freezing, during the same day. The samples are accepted every day from 10 to 13h. It is possible to deliver the sample via post express service. The analysis is performed within 10 working days. The results and the bill are sent to the patient's home address, or can be collected personally at the Institute from 10 to 16h every day.

For payment instructions, please contact us.


  • dr Tatjana Kostić
  • dr Nataša Tošić
  • dr Sonja Pavlović

Tel: +381 11 3976 445
Mob: +381 65 3976 445
Fax: +381 11 3975 808

Please publish modules in offcanvas position.